Keros Therapeutics, Inc. Payments of Stock Issuance Costs
Keros Therapeutics, Inc. (KROS) reported Payments of Stock Issuance Costs of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-03-04
- Keros Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2025-03-31 was $9.94M.
- Keros Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2021-09-30 was $0.00.
- Keros Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- Keros Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- Keros Therapeutics, Inc. payments of stock issuance costs for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Keros Therapeutics, Inc. payments of stock issuance costs for fiscal 2024 was $171.00K, a 81.91% increase from fiscal 2023.
- Keros Therapeutics, Inc. payments of stock issuance costs for fiscal 2023 was $94.00K, a 8.05% increase from fiscal 2022.
- Keros Therapeutics, Inc. payments of stock issuance costs for fiscal 2022 was $87.00K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-04 | |||
| 2025-03-31 | $9.94M 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $171.00K 10-K · filed 2026-03-04 | |||
| 2023-12-31 | $94.00K 10-K · filed 2025-02-26 | |||
| 2022-12-31 | $87.00K 10-K · filed 2025-02-26 | |||
| 2022-06-30 | $153.00K 10-Q · filed 2022-08-04 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | $0.00 derived: sum of 3 quarters · filed 2021-08-05 | $0.00 derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-06 | $0.00 derived: sum of 2 quarters · filed 2021-05-06 | $0.00 derived: sum of 3 quarters · filed 2021-11-04 | $8.00K derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $8.00K derived: sum of 3 quarters · filed 2021-11-04 | $227.00K 10-K · filed 2021-03-25 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $8.00K derived: sum of 2 quarters · filed 2021-11-04 | $227.00K 10-Q · filed 2021-11-04 | $227.00K derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $227.00K 10-Q · filed 2021-08-05 | $227.00K derived: sum of 3 quarters · filed 2021-08-05 | $227.00K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $219.00K 10-Q · filed 2021-05-06 | $219.00K derived: sum of 2 quarters · filed 2021-05-06 | $219.00K derived: sum of 3 quarters · filed 2021-05-06 | $219.00K derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $0.00 10-K · filed 2021-03-25 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $0.00 derived: sum of 2 quarters · filed 2020-11-10 | $0.00 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $0.00 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |